



Sparking Progress: *Deloitte advances Generative AI for enterprises with NVIDIA NIM Agent Blueprints*

Enterprise adoption of artificial intelligence (AI) and Generative AI (GenAI) is strong and on the rise. Recent surveys indicate 43% of Fortune 500 CEOs have already implemented GenAI in their organizations to drive revenue¹, while another 86% of companies using the technology have reported a 6% revenue increase since adoption².

As AI proves increasingly useful, new tools and services can help organizations accelerate GenAI adoption and time to value. For example, [NVIDIA NIM Agent Blueprints](#) introduces a catalog of pretrained, customizable AI workflows that equip enterprise developers with a software suite for building and deploying GenAI applications. The blueprints can help with retrieval-augmented generation (RAG), customer service chatbots, drug discovery screening, and many other use cases.

NIM Agent Blueprints signify the next important wave of GenAI innovation—a wave made possible through industry collaborations, including Deloitte's work with NVIDIA.

This chapter of our collaboration builds on a long history of Deloitte's work with NVIDIA to develop innovative AI solutions for enterprises. *For example:*

- Deloitte's entire suite of [Quartz AI™ cross-industry AI service offerings](#) are supported with NVIDIA's first three NIM Agent Blueprints. We collaborated closely with NVIDIA to integrate the microservices into these solutions.
- Deloitte's AI Ambassador program for GenAI incubation—introduced with the first wave of GPT large language models (LLMs) and [NVIDIA NeMo](#) Retriever microservices—provided software and models to enable RAG functionality for enterprises to effectively utilize their data to enhance AI applications.
- [Deloitte's Frontline AI™ solution](#), originally developed on the NVIDIA Tokkio reference architecture, delivers on the capabilities of the NIM Blueprint for digitally based, customer service chatbots. This solution turns online assistance into faster, more meaningful customer experiences using digital avatars that interact with users in real time, providing answers and feedback based on innovative architectures.
- The NVIDIA NIM Blueprint for drug discovery works with [Deloitte's Atlas AI™ solution](#), built on the [NVIDIA BioNeMo](#) LLM. By using AI to rapidly generate 3D biomolecular structures and predict drug-to-protein binding, this solution unlocks comprehensive research capabilities that can help scientists and researchers make bigger drug breakthroughs faster—a solution exclusively from Deloitte, powered by NVIDIA.

But our work with NVIDIA isn't finished. As Deloitte US CEO Jason Girzadas said, "By embedding NVIDIA NIM Agent Blueprints into enterprise solutions built on NVIDIA NIM microservices, we are engaging with our clients to innovate faster, unlock new growth opportunities, and define AI-competitive advantage."

Are you ready to join us on the journey?

Visit our [alliance page](#) to learn how your organization can get involved today

1. <https://www2.deloitte.com/content/dam/Deloitte/us/Documents/2024-Fortune-Deloitte-CEO-Survey.pdf>
2. <https://venturebeat.com/ai/86-of-enterprises-see-6-revenue-growth-with-gen-ai-use-according-to-google-cloud-survey/>

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor.

Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.

© 2024 Deloitte Development LLC. All rights reserved.